State of New Jersey Common Pension Fund D continued to hold its position in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent filing with the SEC. The firm owned 490,000 shares of the medical equipment provider’s stock at the end of the second quarter. State of New Jersey Common Pension Fund D’s holdings in Boston Scientific Corporation were worth $13,583,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bronfman E.L. Rothschild L.P. boosted its position in Boston Scientific Corporation by 7.2% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 5,041 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 338 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Boston Scientific Corporation by 10.3% in the first quarter. Quadrant Capital Group LLC now owns 5,201 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 487 shares during the last quarter. Guardian Life Insurance Co. of America boosted its position in Boston Scientific Corporation by 0.9% in the first quarter. Guardian Life Insurance Co. of America now owns 5,266 shares of the medical equipment provider’s stock valued at $131,000 after buying an additional 49 shares during the last quarter. Parametrica Management Ltd purchased a new position in shares of Boston Scientific Corporation during the second quarter valued at $219,000. Finally, Commerce Bank purchased a new position in shares of Boston Scientific Corporation during the first quarter valued at $207,000. 92.08% of the stock is owned by institutional investors.

Shares of Boston Scientific Corporation (NYSE:BSX) opened at 26.51 on Wednesday. The company has a 50-day moving average price of $27.55 and a 200 day moving average price of $25.94. The stock has a market capitalization of $36.33 billion, a P/E ratio of 47.42 and a beta of 1.09. Boston Scientific Corporation has a 52 week low of $19.67 and a 52 week high of $28.51.

Boston Scientific Corporation (NYSE:BSX) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm earned $0.27 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. Analysts forecast that Boston Scientific Corporation will post $1.26 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/09/state-of-new-jersey-common-pension-fund-d-has-13583000-stake-in-boston-scientific-corporation-bsx.html.

Several research analysts recently weighed in on BSX shares. Stifel Nicolaus raised their target price on Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “hold” rating in a research note on Wednesday, June 28th. BidaskClub cut Boston Scientific Corporation from a “strong-buy” rating to a “buy” rating in a research note on Thursday, July 6th. Zacks Investment Research raised Boston Scientific Corporation from a “sell” rating to a “hold” rating in a research note on Monday, April 24th. Oppenheimer Holdings, Inc. set a $29.00 target price on Boston Scientific Corporation and gave the company a “hold” rating in a research note on Friday, July 28th. Finally, Royal Bank Of Canada raised their target price on Boston Scientific Corporation from $29.00 to $31.00 and gave the company an “outperform” rating in a research note on Friday, June 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Boston Scientific Corporation has an average rating of “Buy” and a consensus target price of $30.06.

In other news, SVP Wendy Carruthers sold 12,433 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $26.75, for a total value of $332,582.75. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael P. Phalen sold 15,500 shares of the business’s stock in a transaction dated Thursday, June 29th. The shares were sold at an average price of $28.02, for a total value of $434,310.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 236,489 shares of company stock valued at $6,440,888. Insiders own 0.74% of the company’s stock.

Boston Scientific Corporation Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX).

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.